You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
|
---|---|
Published in |
New England Journal of Medicine, October 2009
|
DOI | 10.1056/nejmoa0907845 |
Pubmed ID | |
Authors |
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, Mark E Cooper, Dick de Zeeuw, Kai-Uwe Eckardt, Jan M Feyzi, Peter Ivanovich, Reshma Kewalramani, Andrew S Levey, Eldrin F Lewis, Janet B McGill, John J V McMurray, Patrick Parfrey, Hans-Henrik Parving, Giuseppe Remuzzi, Ajay K Singh, Scott D Solomon, Robert Toto |
Abstract |
Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested. |
X Demographics
The data shown below were collected from the profiles of 31 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 9 | 29% |
United States | 5 | 16% |
Mexico | 1 | 3% |
Ireland | 1 | 3% |
Colombia | 1 | 3% |
India | 1 | 3% |
Malaysia | 1 | 3% |
Australia | 1 | 3% |
Japan | 1 | 3% |
Other | 0 | 0% |
Unknown | 10 | 32% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 17 | 55% |
Practitioners (doctors, other healthcare professionals) | 10 | 32% |
Science communicators (journalists, bloggers, editors) | 2 | 6% |
Scientists | 2 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 576 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 7 | 1% |
Australia | 4 | <1% |
Italy | 2 | <1% |
Brazil | 2 | <1% |
France | 1 | <1% |
Uruguay | 1 | <1% |
Chile | 1 | <1% |
United Kingdom | 1 | <1% |
Egypt | 1 | <1% |
Other | 5 | <1% |
Unknown | 551 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 89 | 15% |
Other | 66 | 11% |
Student > Ph. D. Student | 62 | 11% |
Student > Bachelor | 48 | 8% |
Student > Postgraduate | 38 | 7% |
Other | 151 | 26% |
Unknown | 122 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 287 | 50% |
Agricultural and Biological Sciences | 30 | 5% |
Biochemistry, Genetics and Molecular Biology | 23 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 21 | 4% |
Nursing and Health Professions | 19 | 3% |
Other | 64 | 11% |
Unknown | 132 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 114. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2023.
All research outputs
#371,450
of 25,639,676 outputs
Outputs from New England Journal of Medicine
#5,571
of 32,591 outputs
Outputs of similar age
#822
of 108,999 outputs
Outputs of similar age from New England Journal of Medicine
#14
of 176 outputs
Altmetric has tracked 25,639,676 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,591 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.6. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 108,999 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.